LMOD2

LMOD2 is a striated muscle actin-binding protein that elongates sarcomeric thin filaments by promoting actin assembly and dynamics at thin filament pointed ends in the heart (PMID:26487682). Loss of LMOD2 produces abnormally short, non-uniform thin filaments with severely reduced contractile force, and its level is dose-dependently coupled to thin filament length and force output, with rapid cardiac failure upon depletion (PMID:26487682, PMID:30102883). Homozygous loss-of-function variants in human LMOD2 abolish protein production, yield extraordinarily short cardiac thin filaments, and cause neonatal dilated cardiomyopathy, establishing LMOD2 as a Mendelian DCM gene (PMID:31517052, PMID:35082396). Beyond the heart, LMOD2 specifically regulates the length of a distal nebulin-free thin filament segment in slow skeletal muscle and, through direct interaction with the actin ACTC1, controls myogenic differentiation, fiber-type composition, and myoblast proliferation (PMID:33177085, PMID:40745266). LMOD2 abundance is set post-translationally: SNX17 binds LMOD2 and protects it from lysosomal degradation (PMID:33933636).

1. 2015 High

   Established the core function of LMOD2 — how cardiac thin filaments reach mature length — by showing it drives actin assembly at pointed ends and that its loss shortens filaments and impairs contraction.

   Evidence Germline knockout mouse with micropillar force measurements and AAV-mediated GFP-Lmod2 rescue

   PMID:26487682

   Open questions at the time

   • Did not resolve the biochemical mechanism of pointed-end actin elongation at atomic detail
   • Adult versus developmental requirement not separated
2. 2016 Medium

   Extended LMOD2's role beyond thin filaments by linking its loss to intercalated disc integrity, showing sarcomere disorganization coincides with disrupted cell-cell junctional gene expression.

   Evidence PiggyBac insertional mouse mutant with electron microscopy and expression analysis of β-catenin and Connexin43

   PMID:27274810

   Open questions at the time

   • Whether ICD defects are direct or secondary to thin filament disarray unresolved
   • No direct LMOD2 interaction with ICD components shown
3. 2018 High

   Resolved whether LMOD2 is needed for ongoing function in mature heart and quantified the relationship between its level and contractile output, demonstrating a steep dose-dependence.

   Evidence Cardiac-specific conditional knockout mouse with isolated trabeculae force measurements

   PMID:30102883

   Open questions at the time

   • Molecular basis of why <20% suffices not explained
   • Length-dependent activation defect mechanism not dissected
4. 2019 Medium

   Confirmed the mouse-derived mechanism operates in humans by showing a nonsense variant ablates LMOD2 protein, shortens thin filaments, and reduces force in patient cardiomyocytes.

   Evidence Patient exome sequencing with explanted heart histology and isolated cardiomyocyte force measurements

   PMID:31517052

   Open questions at the time

   • Single patient case
   • Genotype-phenotype range across LMOD2 variants not defined
5. 2020 Medium

   Defined the division of labor between LMOD2 and nebulin in skeletal muscle, showing LMOD2 governs a nebulin-free distal thin filament segment specifically in slow muscle.

   Evidence Nebulin super-repeat targeted gene editing in mice with high-resolution thin filament structural analysis

   PMID:33177085

   Open questions at the time

   • Single lab
   • Mechanism of fiber-type-specific LMOD2 dependence not established
6. 2021 Medium

   Identified how LMOD2 protein abundance is controlled, showing SNX17 binds LMOD2 and shields it from lysosomal degradation, with loss of this protection worsening cardiac dysfunction.

   Evidence Co-immunoprecipitation, lysosomal pathway inhibition, and SNX17 knockdown in NRVMs and rat model

   PMID:33933636

   Open questions at the time

   • Single Co-IP for the interaction without reciprocal validation
   • E3 ligase or trafficking route targeting LMOD2 to lysosome unidentified
7. 2022 Medium

   Reinforced human pathogenicity through an independent splice-site variant that abolishes full-length LMOD2 and produces short thin filaments and lethal DCM.

   Evidence Pre-mRNA splicing studies, western blot, and immunostaining of proband heart tissue plus HEK293 construct transfection

   PMID:35082396

   Open questions at the time

   • Single family
   • No therapeutic intervention tested
8. 2025 Medium

   Broadened LMOD2 function into skeletal myogenesis by demonstrating a direct ACTC1 interaction and roles in differentiation, fiber-type composition, and proliferation, with MyoG identified as an upstream transcriptional regulator.

   Evidence Co-IP, CRISPR knockout in C2C12 cells, in vivo lentiviral knockdown, RNA-seq, and transcription factor binding analysis

   PMID:40745266

   Open questions at the time

   • Single Co-IP for ACTC1 interaction
   • Whether myogenic effects reflect thin filament function or a separate role unclear

• The atomic-level mechanism by which LMOD2 nucleates and elongates actin at thin filament pointed ends, and how its filament-length and myogenic differentiation roles are mechanistically connected, remain unresolved.
• No structural model of LMOD2 on the pointed end
• Degradation machinery beyond SNX17 unidentified
• Causal link between contractile and differentiation phenotypes untested